Condition: Urothelial Carcinoma · Sponsor: Peking University First Hospital
This study is an ambispective cohort observational study to analyze the efficacy of adjuvant radioimmunotherapy (radiotherapy and immunotherapy) compared with adjuvant chemotherapy in patients with the upper urinary tract urothelial carcinoma with high-risk factors (postoperative pathology suggestive of pT2 and above, N+, G3/high-grade and multiple tumors, positive cut margins). A subgroup analysis was performed to obtain the population of patients who might benefit from different treatment approaches. Patients with high risk factors for postoperative recurrence or metastasis will be treated with relevant adjuvant therapy, which in turn will benefit patients.
This description comes directly from the study's public registry record.
Xuesong Li, M.D. · +86-15801399116 · pineneedle@sina.com
Chunru Xu, M.D. · +8617812172086 · xcrbdyy@126.com
Always discuss trial participation with your own doctor first.
| Departmeng of Urology, Peking University First Hospital | Beijing, China | Recruiting |
| Department of Medical Oncology, Peking University First Hospital | Beijing, China | Recruiting |
| Department of Radiotherapy Oncology, Peking University First Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06120374